دورية أكاديمية
أعرض في EDS

Role of mTOR Inhibitors in Kidney Disease

التفاصيل البيبلوغرافية
العنوان: Role of mTOR Inhibitors in Kidney Disease
المؤلفون: Moto Kajiwara, Satohiro Masuda
المصدر: International Journal of Molecular Sciences, Vol 17, Iss 6, p 975 (2016)
بيانات النشر: MDPI AG, 2016.
سنة النشر: 2016
المجموعة: LCC:Biology (General)
LCC:Chemistry
مصطلحات موضوعية: mTOR inhibitor, kidney, renal cancer, diabetic nephropathy, kidney transplantation, Biology (General), QH301-705.5, Chemistry, QD1-999
الوصف: The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui). Because sirolimus showed antiproliferative activity, researchers investigated its molecular target and identified the TOR1 and TOR2. The mTOR consists of mTOR complex 1 (mTORC1) and mTORC2. Rapalogues including sirolimus, everolimus, and temsirolimus exert their effect mainly on mTORC1, whereas their inhibitory effect on mTORC2 is mild. To obtain compounds with more potent antiproliferative effects, ATP-competitive inhibitors of mTOR targeting both mTORC1 and mTORC2 have been developed and tested in clinical trials as anticancer drugs. Currently, mTOR inhibitors are used as anticancer drugs against several solid tumors, and immunosuppressive agents for transplantation of various organs. This review discusses the role of mTOR inhibitors in renal disease with a particular focus on renal cancer, diabetic nephropathy, and kidney transplantation.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1422-0067
Relation: http://www.mdpi.com/1422-0067/17/6/975; https://doaj.org/toc/1422-0067
DOI: 10.3390/ijms17060975
URL الوصول: https://doaj.org/article/39a2e81f18bb423886c6529a590d14a4
رقم الأكسشن: edsdoj.39a2e81f18bb423886c6529a590d14a4
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:14220067
DOI:10.3390/ijms17060975